Madrigal Pharmaceuticals reports a narrower-than-expected Q2 loss and revenue growth of 71.2% year-over-year.
Madrigal Pharmaceuticals posted a Q2 GAAP loss per share of $1.99, beating estimates by $0.65. Revenue reached $364.3 million, up 71.2% from the same period last year and exceeding expectations by $11.13 million.
The company’s net loss included $25.0 million in one-time, upfront business development expenses, equating to $0.86 per share. Analysts had anticipated weaker earnings and revenue performance for the quarter.
Shares may react positively to the earnings beat and strong revenue growth, though the net loss remains a key focus for investors.